TX-ZILLIANT
2.12.2021 09:32:25 CET | Business Wire | Press release
Zilliant , the industry leader in intelligent B2B price optimization, price management and sales guidance software, today announced significant growth in Europe, marked by compound annual revenue growth of 55% from 2018-2021 as well as significant growth of new customers.
“B2B company leaders are increasingly seeking alternatives to the traditional means of managing prices and enabling sales teams,” said Zilliant President and Chief Executive Officer Greg Peters. “Tying strategy to effective execution can be even more difficult for companies in Europe, particularly in global, multi-country businesses. Our growth in the region can be attributed to the increased breadth of our product portfolio, addressing the full spectrum of pricing challenges in B2B, and our passion for powering intelligent commerce for our customers.”
Zilliant maintains offices in Paris, London, Milan, Italy, and Walldorf, Germany. In recent years, a wide variety of B2B companies in Europe with worldwide operations have signed on as new Zilliant customers, they include:
- Elektro-Material AG: Part of the Rexel Group and a leading wholesale distributor of electrical parts and supplies.
- Malvern Panalytical: A global provider of analytical solutions for particle, composition and structural characteristics of a variety of materials.
- METRO AG: A leading international wholesale company with food and non-food assortments that specializes on serving the needs of hotels, restaurants and caterers (HoReCa) as well as independent traders.
- Norgren: A manufacturer of pneumatic motion and fluid control products.
- Pirelli: A global, high-value tire company.
- Pro a Pro: A part of METRO Group, is a foodservice distributor based in France with 22 warehouses, more than 40,000 customers in France and overseas, and 2,000 employees.
- Somfy: A global manufacturer in automatic controls for openings and closures in homes and buildings.
- TERREAL: A €630 million building products manufacturer.
- Avantor, delivered by VWR Europe: A global distributor of products for the medical and life sciences industries.
“We greatly appreciate our customers in Europe that have entrusted us to help them power intelligent commerce with our industry-leading cloud-native price optimization and management and sales guidance software,” said Zilliant Vice President of Europe, MEA and Asia Pacific Michel Safi. “Whether it’s creating a greater level of pricing control in a multi-country environment, ensuring price consistency in digital and traditional channels, or deploying new sales programs to sell excess inventory or grow wallet share, we look forward to helping our customers respond faster to dynamic markets in a more intelligent manner.”
For more information about Zilliant’s industry-leading price optimization and management software, please visit www.zilliant.com/2021_idc_marketscape_report/ .
About Zilliant
Zilliant powers intelligent commerce for B2B companies by connecting their commercial strategies with effective execution. Our industry-leading price optimization and management and sales guidance software enables profitable growth by transforming the way
our customers use data to price and sell in traditional and digital channels. Zilliant’s data science, cloud-native software and passion for customer success delivers the highest ROI, fastest time to value and highest customer satisfaction. Learn more about how Zilliant helps power intelligence commerce at www.zilliant.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005127/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom